See the possibilities for your patients.

RPGR Mutation Male: 36 years old

Vista clinical trial eligibility

Your patient may qualify to participate in the VISTA clinical trial, a phase 2/3 study evaluating an investigational gene therapy for the treatment of retinitis pigmentosa. Patients must meet the following criteria:

  • Diagnosis of XLRP confirmed by a healthcare professional
  • Have a mutation in the RPGR gene confirmed by genetic testing
  • Male ages 13-50 years
Healthcare provider brochure

See possibilities, not problems. Take the next step to find out more about resources available for you and your patients.

Clinical Trial Opportunities

The VISTA clinical trial is currently pre-screening male patients between the ages of 12-50 (inclusive) diagnosed with X-linked retinitis pigmentosa (XLRP).

learn more

Genetic Testing

Genetic testing is critical to the diagnosis of patients with Inherited Retinal Disease. Learn more about the free genetic testing that may be available for your patients.

learn more

What is Gene Therapy?

Gene therapy targets the exact cause of a disease and aims to treat the disease through a one-time administration.

learn more

Visionary science for life-changing cures

Beacon Therapeutics is a biotechnology company seeking to transform the lives of patients with lifelong and debilitating eye diseases through its proprietary gene therapy platform.

Our team includes industry-leading experts and innovative thinkers working together on discoveries that we hope will transform the lives of people with inherited eye disorders. In particular, we are studying how to use our gene therapy platform to develop investigational treatments for disorders that are caused by single-gene mutations and that also have a significant effect on a person’s sight.

Learn more about Beacon Tx and their groundbreaking investigational gene therapies for patients with genetic disorders.

Learn more at

To enter the site, please indicate that you are a Healthcare Professional